10-Q: Omada Health Q3 2025: Revenue Soars 49%, Net Loss Narrows

Omada Health reports strong Q3 2025 revenue growth of 49% to $68.0 million, significantly reducing net loss to $3.2 million, driven by increased member enrollment and operational efficiencies.

Summary

• Total revenue increased by 49% to $68.0 million for the three months ended September 30, 2025, compared to $45.5 million for the same period in 2024.
• Total revenue increased by 51% to $184.4 million for the nine months ended September 30, 2025, compared to $121.8 million for the same period in 2024.
• Net loss significantly decreased to $3.2 million for the three months ended September 30, 2025, from $9.2 million in the prior-year period.
• Net loss for the nine months ended September 30, 2025, was $17.9 million, a substantial improvement from $38.9 million in the same period of 2024.
• Gross profit increased by 58% to $45.1 million for the three months ended September 30, 2025, with gross margin expanding by 3.5 percentage points to 66.3%.
• Total members enrolled reached 831,000 as of September 30, 2025, representing a 53% increase from 543,000 members as of September 30, 2024.
• The company successfully completed its Initial Public Offering (IPO) on June 9, 2025, raising $151.6 million in net proceeds after deducting underwriting discounts and offering expenses.
• Outstanding debt under the MidCap Term Facility and MidCap Revolving Facility was fully repaid on July 31, 2025, utilizing a portion of the IPO proceeds, which resulted in a $2.1 million loss on debt extinguishment.
• Management identified material weaknesses in internal control over financial reporting related to inadequate segregation of duties, insufficient personnel with appropriate technical knowledge, and inadequate formalized processes for financial close and reporting.

Sentiment

Score: 7

Explanation: The company demonstrated robust revenue growth and a substantial reduction in net losses, coupled with a successful IPO that significantly boosted liquidity and eliminated debt. However, it continues to operate at a net loss and has identified material weaknesses in its internal financial controls, which require ongoing remediation. The competitive and evolving regulatory landscape also presents notable challenges.

Positives

• Strong revenue growth of 49% for Q3 2025 ($68.0 million) and 51% for the nine months ended September 30, 2025 ($184.4 million).
• Significant reduction in net loss from $9.2 million to $3.2 million in Q3 2025, and from $38.9 million to $17.9 million for the nine months ended September 30, 2025.
• Gross margin expanded by 3.5 percentage points to 66.3% in Q3 2025 and by 5.5 percentage points to 63.6% for the nine months, driven by Care Team efficiency initiatives and expanded use of supporting technologies.
• Substantial increase in total members to 831,000 as of September 30, 2025, a 53% increase from the prior year.
• Successful completion of the IPO on June 9, 2025, generating $151.6 million in net proceeds.
• Full repayment of the MidCap Term Facility and MidCap Revolving Facility on July 31, 2025, improving liquidity and reducing future interest expense.
• Increased cash and cash equivalents to $198.6 million as of September 30, 2025, from $76.4 million at December 31, 2024.
• Positive interest income of $2.0 million in Q3 2025, a significant increase from $17 thousand in Q3 2024, primarily due to interest earned from IPO proceeds.

Negatives

• The company continues to incur net losses, reporting $3.2 million in Q3 2025 and $17.9 million for the nine months ended September 30, 2025.
• A $2.1 million loss on debt extinguishment was recognized due to the early repayment of the MidCap Credit Agreement.
• Material weaknesses in internal control over financial reporting were identified, specifically concerning inadequate segregation of duties, insufficient technical accounting personnel, and informal financial close processes.
• Operating loss was $2.5 million in Q3 2025 and $15.3 million for the nine months ended September 30, 2025.
• Hardware cost of revenue increased by 63% in Q3 2025 and 50% for the nine months, outpacing hardware revenue growth in Q3 (49%).
• Sales and marketing expenses increased by 31% for both the three and nine months ended September 30, 2025, driven by administrative and marketing fees to channel partners and personnel costs.
• General and administrative expenses increased by 35% in Q3 2025 and 24% for the nine months, partly due to higher bad debt expenses and costs associated with operating as a public company.
• Change in fair value of warrant liabilities resulted in a loss of $0.2 million in Q3 2025 and $1.5 million for the nine months.

Risks

• Limited operating history and challenges in effectively managing rapid growth.
• History of net losses and uncertainty about achieving or maintaining profitability in the future.
• Failure of programs to achieve and maintain market acceptance could result in sales below expectations.
• The virtual care market is new, rapidly evolving, and increasingly competitive, making demand forecasting difficult.
• Competition from existing or potential competitors, some with greater resources, could adversely affect the business.
• Competitive solutions or technological breakthroughs for chronic conditions (e.g., new drugs, AI) may adversely affect demand for programs.
• Business growth relies on the growth and success of customers and channel partners, which are difficult to predict and affected by external factors.
• A decrease in the number of individuals covered by customers or channel partners, or a reduction in covered programs, could lead to declining member enrollment and revenue.
• Revenue depends on member engagement, clinical outcomes, and cost savings, with potential repayment obligations if performance criteria are not met.
• Significant upfront costs are incurred in establishing and expanding customer and channel partner relationships, with a risk of not recovering these costs if relationships are not maintained or grown.
• A substantial portion of sales comes from or through a limited number of customers and channel partners that operate as resellers, creating concentration risk.
• Inability to attract new customers and channel partners or increase member enrollment from existing ones could slow revenue growth.
• Need to increase the size of the organization, including Care Teams, and potential difficulties in managing growth and attracting talent.
• Deterioration in relationships with employees and other service providers could adversely impact the business.
• Dependence on a limited number of third-party suppliers for devices, cellular device connectivity, and complementary healthcare services.
• Seasonality in business may cause fluctuations in financial results.
• Information technology (IT) systems and those of third-party service providers may fail or suffer cybersecurity incidents, data breaches, and other disruptions.
• Operating in a highly regulated industry, with changes in regulations or implementation of existing regulations potentially affecting operations.
• Use and disclosure of personal information, including health information, is subject to federal and state privacy and security laws (e.g., HIPAA, CCPA), with non-compliance leading to significant liability or reputational harm.
• Failure to comply with federal and state healthcare regulatory laws (e.g., Anti-Kickback Statute, Stark Law, False Claims Act) could result in penalties.
• Legislative or regulatory healthcare reforms or reductions in government spending (e.g., OBBBA, ACA changes) may make it more difficult and costly to produce, market, and distribute programs.
• Programs may result in member harm or injury, leading to medical liability claims.
• Any disruption of service at third-party data centers and hosting providers (e.g., Amazon Web Services) could interrupt or delay program delivery.
• Dependence on a limited number of third-party manufacturers and suppliers operating in international markets exposes the company to foreign operational and political risks (e.g., tariffs, trade disputes).
• Inability of manufacturers and suppliers to procure raw materials or produce devices could impact the business.
• Adverse effects from natural disasters and other catastrophic events.
• Risks related to credit card and debit card payments.
• Use of AI and machine learning poses risks due to a changing regulatory landscape, performance issues, and competition.
• Failure to attract and retain senior leadership and key clinical, scientific, and technology employees.
• Reliance on a direct sales force, with potential difficulties in maintaining or expanding it.
• A decline in the prevalence of employer-sponsored healthcare could adversely affect the business.
• Long and unpredictable sales and implementation cycles, leading to difficult-to-forecast sales and revenue.
• Failure to offer high-quality support for customers, channel partners, and members.
• Failure to develop widespread brand awareness cost-effectively or widespread negative media coverage.
• Inability to develop and release new programs and services or successful enhancements to existing ones.
• Public opinion and scrutiny of treatments for obesity and overweight (e.g., GLP-1s) may impact public perception of the company and its offerings.
• International expansion would introduce additional business, political, regulatory, operational, financial, and economic risks.
• Inability to successfully execute growth initiatives, business strategies, or operating plans.
• Risk that licensed physical therapists providing services to members could be characterized as employees, adversely affecting the business.
• Subject to risks from legal and arbitration proceedings.
• Failure to comply with the FCPA, economic and trade sanctions regulations, and similar laws.
• Changes in the regulation of the Internet could adversely affect the business.
• Ability to use net operating loss carryforwards (NOLs) and other tax attributes may be limited due to Internal Revenue Code Sections 382 and 383.
• Effective tax rate may vary significantly from period to period.
• Changes in tax laws or tax rulings could adversely affect effective tax rates, results of operations, and financial condition.
• Applicability of sales, use, and other tax laws or regulations on the business is uncertain, potentially leading to additional tax liability.
• Cash deposits with financial institutions exceed insured limits, posing a risk in the event of bank failures.
• Changes in accounting principles or their interpretation by FASB affecting consolidation of entities (e.g., Physera Physical Therapy Group, PC) could impact reported revenues.
• The market price of common stock may be volatile.
• As an emerging growth company, reduced reporting requirements may make common stock less attractive to investors.
• Increased costs and additional regulations as a public company.
• Principal stockholders and management own a significant percentage of stock and can exert significant control.
• Sales of a substantial number of shares of common stock in the public market could cause the stock price to fall.
• Provisions in charter documents and under Delaware law could discourage a takeover.
• Claims for indemnification by directors, officers, and other employees may reduce available funds.
• Exclusive forum provisions in charter documents could limit stockholders' ability to obtain a favorable judicial forum for disputes.
• Reliance on research and reports from industry or securities analysts, with adverse opinions potentially causing stock price decline.
• Engaging in acquisitions or strategic transactions or partnerships may increase capital requirements, dilute stockholders, or incur debt/contingent liabilities.
• Economic uncertainties or downturns could disproportionately affect demand for programs.

Future Outlook

The company expects to continue focusing on long-term growth of its core business while selectively investing in platform, programs, and operations enhancements. Management anticipates continued investments in the virtual care platform and expects general and administrative expenses to increase due to public company operations. Current cash and cash equivalents are believed to be sufficient to fund operations for at least the next 12 months, but additional financing through equity or debt may be sought if future capital requirements increase. The evolving GLP-1 treatment landscape is seen as a potential driver for increased interest in cardiometabolic programs, though it also presents risks of demand fluctuations and negative public perception. The company is currently assessing the impact of the One Big Beautiful Bill Act (OBBBA) enacted in July 2025, which includes significant tax provisions with various effective dates through 2027.

Management Comments

• "Our mission is to bend the curve. Our hope is that, one day, tomorrows epidemiologists will notice a bend in disease curves, wonder what might be happening, and conclude that part of that impact has been Omada."
• "We strive to inspire and enable people to make lasting health changes on their own terms."
• "We deliver virtual care between doctors visits, providing an engaging, personalized, and integrated experience for our members that is designed to improve their health while delivering value for the employers, health plans, health systems, pharmacy benefit managers (PBMs), and other entities that cover the cost of our programs."
• "We believe our programs serve a clear need for our customers and channel partners as well as our members, which is reinforced by our strong customer satisfaction and member engagement rates."
• "We believe that our future growth, success, and performance are dependent on many factors, including... acquisition of new customers and channel partners, customer and channel partner retention, program expansion within existing customer base, member enrollment, member engagement and outcomes, and investments in growth."
• "We believe that current macroeconomic factors, including the impact of inflation and tariffs, are impacting customer and channel partner spending decisions."
• "We believe that our current cash and cash equivalents will be sufficient to fund our operations for at least the next 12 months."

Industry Context

The virtual care market is characterized as new, unproven, rapidly evolving, and increasingly competitive. The U.S. healthcare industry is undergoing significant structural changes, driven by rising costs, a shift towards patient-centricity, and technological advancements, which are fueling demand for personalized healthcare solutions. The GLP-1 treatment landscape is new and rapidly expanding, with combined global sales of key GLP-1 drugs reaching approximately $41.4 billion in 2024, a 73% increase from 2023. This growth, coupled with FDA guidance for concurrent behavioral and lifestyle treatment plans, is expected to increase interest in cardiometabolic programs like Omada's. The company faces competition from various digital health companies offering cardiometabolic and musculoskeletal programs, as well as large, well-financed healthcare providers and health plans developing their own platforms. The regulatory environment is becoming more stringent, with increasing scrutiny on healthcare costs and evolving frameworks for AI technologies, including new federal and state laws.

Comparison to Industry Standards

• The filing mentions competitors in the cardiometabolic space such as Hello Heart Inc., Lark Technologies, Inc., Livongo (via Teladoc Health, Inc.), Onduo LLC, Vida Health, Inc., and Virta Health Corp.
• Competitors in the musculoskeletal (MSK) program space include Hinge Health, Inc. and SWORD Health, Inc.
• The filing notes that some competitors may have greater resources, market share, or offer solutions at more attractive prices, but does not provide specific comparable financial or operational results for these companies to assess Omada's performance against industry benchmarks.

Corporate Governance

Legal Proceedings

• The company is not presently a party to any litigation the outcome of which, if determined adversely, would individually or taken together, have a material adverse effect on its business, operating results, cash flows, or financial condition.
• From time to time, the company may become subject to legal proceedings, claims, and litigation arising in the ordinary course of business.

Related Party Transactions

• Accounts receivable, net includes $29.3 million from a related party as of September 30, 2025, compared to $13.2 million as of December 31, 2024.
• Accrued expenses and other current liabilities include $5.2 million from a related party as of September 30, 2025, compared to $2.2 million as of December 31, 2024.
• Deferred revenue includes $20.3 million from a related party as of September 30, 2025, compared to $13.2 million as of December 31, 2024.
• Services revenue includes $41.8 million from a related party for Q3 2025 (vs. $23.5 million for Q3 2024) and $108.2 million for 9M 2025 (vs. $62.1 million for 9M 2024).
• Hardware revenue includes $3.0 million from a related party for Q3 2025 (vs. $1.7 million for Q3 2024) and $9.0 million for 9M 2025 (vs. $4.7 million for 9M 2024).
• Cost of services revenue includes $1.4 million from a related party for Q3 2025 (vs. $0.8 million for Q3 2024) and $3.8 million for 9M 2025 (vs. $2.5 million for 9M 2024).
• Research and development expenses include $0.6 million from a related party for Q3 2025 (vs. $0.5 million for Q3 2024) and $1.6 million for 9M 2025 (vs. $1.3 million for 9M 2024).
• Sales and marketing expenses include $7.1 million from a related party for Q3 2025 (vs. $3.8 million for Q3 2024) and $19.3 million for 9M 2025 (vs. $11.0 million for 9M 2024).
• General and administrative expenses include $0.4 million from a related party for Q3 2025 (vs. $0.3 million for Q3 2024) and $1.1 million for 9M 2025 (vs. $0.8 million for 9M 2024).
• Affiliates of The Cigna Group beneficially own more than 5% of the company's outstanding capital stock through Cigna Ventures, LLC.
• Sales from or through the top five health plan and PBM partners (including Cigna affiliates) represented 76% of revenue for Q3 2025 (vs. 70% for Q3 2024) and 75% for 9M 2025 (vs. 69% for 9M 2024).
• Partner A (an affiliate of The Cigna Group) accounted for 20% of accounts receivable, net and 32% of revenue for Q3 2025.
• Partner B (an affiliate of The Cigna Group) accounted for 50% of accounts receivable, net and 34% of revenue for Q3 2025.

Stakeholder Impact

• Shareholders: Experienced positive impact from the successful IPO, increased liquidity, and debt repayment. However, face potential dilution from future equity raises and stock price volatility due to market conditions and insider sales after lock-up expiration. Exclusive forum provisions may limit legal recourse.
• Employees: The company is growing headcount and implementing efficiency initiatives for Care Teams. Management (CEO, CFO, President, CAO) adopted Rule 10b5-1 trading plans for future stock sales. There is a risk of unionization.
• Customers/Channel Partners: Continued strong adoption of programs is indicated by revenue growth. However, there is a concentration risk due to significant reliance on a limited number of key partners (Cigna affiliates). Contracts may be terminated if performance targets are not met or if partners switch to competitors.
• Members: Benefit from increased enrollment in virtual care programs designed to improve health outcomes for chronic conditions. Risks include potential harm or injury from programs, dissatisfaction due to system failures, or negative public perception of virtual care or GLP-1 therapies.
• Creditors: The company's credit risk has significantly decreased due to the full repayment of outstanding debt under the MidCap Credit Agreement.

Next Steps

• Continue to focus on long-term growth of the core business.
• Selectively invest in areas that enhance the platform, programs, or operations.
• Monitor the needs of customers and channel partners to respond organically or through partnerships and potential acquisitions.
• Make continued investments in the virtual care platform.
• Address material weaknesses in internal control over financial reporting by implementing processes and controls, hiring additional personnel, and refining financial reporting procedures.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements.
• Evaluate the impact of new accounting pronouncements, including ASU 2023-09 (Income Tax Disclosures), ASU 2024-03 (Income Statement Expenses), ASU 2025-05 (Credit Losses), and ASU 2025-06 (Internal-Use Software).

Key Dates

Recommendation

While Omada Health demonstrates impressive revenue growth and a substantial reduction in net losses, indicating strong operational improvements and market traction, the company remains unprofitable. The successful IPO and debt repayment significantly bolster its financial position, but the concentration of revenue with a few key partners and identified material weaknesses in internal controls present notable risks. The evolving and competitive virtual care market, coupled with regulatory uncertainties around AI and GLP-1 therapies, suggests a 'hold' recommendation. Investors should monitor the company's progress in achieving sustained profitability, remediating internal control issues, and diversifying its customer base before considering a stronger position.

Keywords

Virtual care, Digital health, Cardiometabolic, Prediabetes, Diabetes, Hypertension, Musculoskeletal, MSK, GLP-1, Weight management, Health coaching, SEC filing, 10-Q, Financial results, IPO, Cigna, Healthcare technology, Remote health, Operational efficiency, Net loss reduction